Clinical trial Recruiting at 6 sites Observational Ages 50 and up

Digital screening plus blood biomarkers to detect early Alzheimer's changes

Official title: Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study

Run by Xuanwu Hospital, Beijing · NCT07284264 · Data updated 2026-11-12

This project will test whether a two-step approach—quick digital cognitive screening followed by blood-based biomarker tests—can find early Alzheimer's pathology in community-dwelling adults aged 50 and older who do not have diagnosed cognitive disorders.

Quick facts

Study typeObservational
Ages50 Years and up
SexAll
Enrollment6000 (estimated)
SponsorXuanwu Hospital, Beijing
Academic / other
Locations6 sites (Beijing and 5 other locations)
StatusRecruiting
StartedAugust 15, 2025
Main results expectedJanuary 1, 2026
Study endsJanuary 1, 2026
Registry record updatedDecember 16, 2025
Trial IDNCT07284264 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are community-dwelling adults aged 50 or older in the study regions who have no prior diagnosis of cognitive impairment, can communicate in Chinese, and are willing to complete digital tests and blood sampling.

Probably not a fit

People with an established diagnosis of dementia or severe mental illness, those who cannot complete digital cognitive assessments, non-Chinese speakers, or long-term institutionalized patients are unlikely to benefit from this screening approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study uses a stepwise screening strategy beginning with rapid digital pre-screening that combines the SCD-9 questionnaire, a brief digital cognitive assessment, and a predictive risk model to identify people at higher dementia risk. Individuals flagged by the digital screen proceed to blood-based biomarker testing to confirm Alzheimer’s pathology, with multiple novel blood markers compared head-to-head for diagnostic utility. The study recruits community-dwelling adults aged 50 and older without prior diagnoses of mild cognitive impairment or dementia across several medical centers in China. Results aim to identify which combinations of digital measures and blood biomarkers work best for early, scalable detection in real-world community settings.

Why it matters

Potential benefit: If successful, this approach could enable earlier, simpler, and more scalable detection of Alzheimer's pathology using routine digital screening combined with blood tests, allowing earlier support or preventive strategies.

How similar studies have gone: Previous research has shown promising results for plasma Alzheimer's biomarkers and digital cognitive tests, but direct head-to-head comparisons of multiple novel blood markers in large community screening programs remain relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. adults aged 50 and above;
2. living in community for at least one year and having established medical records;
3. denying a history of cognitive disorders (mild cognitive impairment, dementia, Alzheimer's disease, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.);
4. agreeing to participate in the study;
5. individual or their relatives can communicate normally in Chinese.
6. high-risk groups for dementia(including:1. Complaints of cognitive decline and/or statements by the informant;2. History of AD in first-degree relatives;3. Known ApoE e4 carrier.)

Exclusion Criteria:

1. Self-reporting or confirmation through inquiry indicates the presence of severe mental disorders, such as bipolar disorder or schizophrenia, etc.
2. Having a disease that makes it impossible to complete the cognitive assessment.

Where it's running

  • Xuanwu Hospital, Capital Medical University
    Beijing, China
    Recruiting
  • Hainan Medical University
    Hainan, China
    Recruiting
  • General Hospital of Ningxia Medical University
    Ningxiang, China
    Recruiting
  • The First Hospital of China Medical Unversity
    Shenyang, China
    Recruiting
  • Shenzhen Center For Chronic Disease Control
    Shenzhen, China
    Recruiting
  • Yichun People'S Hospital
    Yichun, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.